Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER

NCT02003924 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02003924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02003924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2013
Completion date
November 28, 2025
Enrollment
1,401 (actual)
Sites
397

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate, nonmetastatic castration-resistant prostate cancer, prostate cancer